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ABSTRACT (255 words) 
 
Objectives: To determine the neuroprotective efficacy of the inert gas xenon following traumatic 
brain injury, and to determine whether application of xenon has a clinically relevant therapeutic 
time window. 
Design: Controlled animal study. 
Setting: University research laboratory. 
Subjects: Male C57BL/6N mice (n=196) 
Interventions: 75% xenon, 50% xenon or 30% xenon, with 25% oxygen (balance nitrogen) 
treatment following mechanical brain lesion by controlled cortical impact. 
Measurements & Main Results: Outcome following trauma was measured using: 1) functional 
neurological outcome score, 2) histological measurement of contusion volume, 3) analysis of 
locomotor function and gait.  Our study shows that xenon-treatment improves outcome following 
traumatic brain injury. Neurological outcome scores were significantly (p<0.05) better in xenon-
treated groups in the early phase (24 hours) and up to 4 days after injury.  Contusion volume was 
significantly (p<0.05) reduced in the xenon-treated groups.  Xenon treatment significantly (p<0.05) 
reduced contusion volume when xenon was given 15 minutes after injury or when treatment was 
delayed 1 hour or 3 hours after injury. Neurological outcome was significantly (p<0.05) improved 
when xenon treatment was given 15 minutes or 1 hour after injury. Improvements in locomotor 
function (p<0.05) were observed in the xenon-treated group, 1 month after trauma. 
Conclusions:  These results show for the first time that xenon improves neurological outcome and 
reduces contusion volume following traumatic brain injury in mice.  In this model, xenon 
application has a therapeutic time window of up to at least 3 hours.  These findings support the idea 
that xenon may be of benefit as a neuroprotective treatment in brain trauma patients.  
Key words: xenon, neuroprotection, inert gases, head trauma, brain injury 
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INTRODUCTION (387 words) 
 
Traumatic brain injury (TBI) affects both young and elderly populations throughout the 
world and results in a significant global healthcare burden.  In developed countries TBI is the main 
cause of death and disability in those aged under 45 [1] with falls and motor-vehicle crashes being 
the leading causes [2, 3].  In the United States, between the years 2002 and 2006, on average 1.7 
million people per year suffered a TBI [4].  Of these, 1.4 million were treated in hospital 
Emergency Departments, 275,000 required hospitalization and survived, but 52,000 died [4]. TBI 
causes 30% of all injury-related deaths in the United States [4].  Current clinical practice for TBI 
patients is largely supportive, centred on non-specific endpoints such as management of tissue 
oxygenation, cerebral perfusion pressure and intracranial pressure [5-8]. At present there are no 
specific pharmacological neuroprotective treatments for TBI [9-12].  Given the high economic costs 
associated with TBI, there is a need for neuroprotective treatments that can minimize or attenuate 
the brain damage following TBI and promote a faster and more complete recovery.  The current 
study evaluates the neuroprotective efficacy of xenon in the rodent controlled cortical impact brain 
trauma model. 
Blunt-trauma TBI is characterized by a “primary injury” determined by the initial 
mechanical force, followed by a “secondary injury” which begins soon after the initial trauma and 
continues to develop in the following hours and days.  The biological processes involved in 
development of secondary injury are complex and involve multiple injury cascades [13, 14], 
however glutamate excitotoxicity, involving overactivation of N-methyl-D-aspartate(NMDA)-
receptors, is thought to play a key role [15-17].   
The noble gas xenon has been used as a general anesthetic since the 1950s [18, 19] but its 
molecular targets were unknown [20]. Following the discovery that xenon is an NMDA receptor 
antagonist [21-24], xenon was shown to be neuroprotective in a number of in vitro and in vivo 
models of ischemic injury [25-34] and xenon is currently undergoing clinical trials as a treatment 
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for ischemic brain injury [35, 36] and post-operative delirum [37]. Information on xenon 
neuroprotection against TBI is much more limited.  In the present study we use the rodent 
controlled cortical impact brain trauma model to test the following hypotheses: that xenon protects 
against secondary injury development; that xenon improves neurological outcome after trauma; and 
that xenon has a clinically relevant therapeutic time window. 
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MATERIALS AND METHODS (1507 words) 
  Adult male C57BL/6N mice aged 2.5 months, mean weight 24 ± 3 g (SEM, n=196), were 
obtained from Charles River Laboratory, Sulzfeld, Germany. Animals were cared for in compliance 
with the institutional guidelines of the Johanes Gutenberg University, Mainz.  All experiments were 
approved by the Animal Ethics Committee of the Landestuntersuchungsamt Rheinland-Pfalz 
(protocol number: G12-1-010). 
 Traumatic brain injury. Animals were anesthetized with 3.5% sevoflurane in an air/oxygen 
mixture (40% O2 / 60% N2) supplied via a facemask in spontaneously breathing animals. Core 
temperature was monitored and maintained at 37°C for the duration of the surgery by means of a 
rectal probe and feedback-controlled heating pad (Hugo Sachs, March-Hugstetten, Germany). 
Traumatic injury was performed using the controlled cortical impact (CCI) model, as described 
previously [38], by an experimenter blinded to the treatment groups. Animals were fixed in a 
stereotactic frame (Kopf Instruments, Tujunga, USA) and a 4mm x 5mm craniotomy window was 
created using a saline-cooled high-speed drill, along the coronal (anterior) and lambdoid (posterior) 
sutures and laterally as close as possible to the temporalis muscle insertion. The bone flap was lifted 
exposing the dura above the right parietal cortex, between the sagittal, lambdoid, and coronal 
sutures. The tip of a custom-built controlled cortical impact device (L. Kopacz, Mainz, Germany) 
was positioned above the intact dura in the centre of the craniotomy window (1mm from saggital 
suture and 1mm from lambdoid suture). The angle of the impactor, typically 25 degrees from the 
sagittal plane, was adjusted such that the tip was perpendicular to the dural surface. An impactor tip 
of diameter 3 mm, impact velocity of 8 m/s and impact duration of 150 ms, were used. In the xenon 
pre-exposure & post-exposure experiments shown in Figure 1 (n=12 animals) a penetration depth of 
1.5 mm was used, in all other experiments (n=184 animals) the penetration depth was 1.0 mm. Our 
pneumatically controlled CCI device is similar in design to that used by Smith et al [39]] and Fox et 
al [40] who developed the CCI model in mice and our impact parameters are similar to those found 
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by those workers to result in moderate injury.  Following CCI-injury, the craniotomy was closed 
with the bone flap, fixed with tissue glue (Histoacryl, Braun-Melsungen, Melsungen, Germany), 
and the skin sutured. Animals were returned to their individual home cages in a heated incubator 
(33°C, 35% humidity; IC8000, Draeger, Germany) and allowed to recover for 15 minutes before 
treatment; during this time they were breathing room air. 
 Experimental groups, randomizing and blinding.  Animals were randomly assigned to 
receive xenon (75%, 50% or 30%) with 25% oxygen (balance nitrogen) or 75% nitrogen : 25% 
oxygen (control gas).  The experimenter performing the CCI surgery was blinded to the treatment. 
A separate experimenter, also blinded to treatment, performed the behavioral tests. Treatment was 
begun 15 minutes, 1 hour, 3 hours or 6 hours after injury. Animals were allowed to survive 24 
hours, 5 days or 1 month.  In the short-term (24 hr) survival experiments we aimed to have 9-10 
animals in each xenon-treatment group.  In some experiments (eg time delay experiments) it was 
not possible to perform all experiments on the same day. In these cases we had additional control 
groups that were pooled resulting in larger numbers of mice in the control groups.  In the 5-day 
survival experiment we had 12 animals in each group; at 24 hours neuroscore data from 24 hour 
survival and 5 day survival experiments was pooled.  Three animals died shortly after CCI injury 
and post-mortem showed evidence of intra-cerebral hemorrhage.  One animal in the 5 day survival 
group became unresponsive and immobile on day 4 and was euthanized, post-mortem indicated 
intra-cerebral hemorrhage. Due to technical issues with the impact device (movement of the 
impactor during CCI, affecting impact parameters) 4 animals were excluded from the dose-response 
analysis (1 in control group, 1 in 30% xenon-group & 2 in 50% xenon-group).  In our long-term (1 
month) survival experiments we had 20 animals each in the xenon and control-treatment groups and 
10 animals in the sham-surgery group, all animals survived and performed Rotarod test, 3 animals 
(one in each group) failed to perform the CatWalk
®
-XT test.  
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 Xenon or control gas administration. Gas treatments were administered to spontaneously 
breathing animals in a series of custom made xenon exposure chambers linked in a closed circuit, 
for a total duration of three hours.  Gas concentrations inside the circuit were monitored 
continuously, via a xenon meter (model 439 EX, Nyquist Ltd, UK) and an oxygen meter (Oxydig, 
Draeger, Luebeck, Germany) included in the circuit.  Carbon dioxide was removed from the system 
by soda lime pellets. Additional volumes of gases were added into the system as necessary to 
maintain their respective concentrations. Gases were circulated at 700 ml/min by a small animal 
ventilator (Inspira ASV, Harvard Apparatus, Holliston, MA, USA). Chambers were housed inside 
an incubator heated to 33°C (Model IC8000, Draeger, Lubeck, Germany).  In the therapeutic time 
window experiments, the start of the 3 hours of xenon-treatment was delayed 15 minutes, 1 hour, 3 
hours, and 6 hours after CCI injury. 
 Physiological measurements.  Systolic and diastolic blood pressure and heart rate were 
measured using a Kent Coda non-invasive blood pressure monitor (EMKA Technologies, Paris, 
France). Temperature measurements were made using an infra-red thermometer (Thermoworks 
model TW2). 
 Histological evaluation. At the end of the observation period (24 hours), and immediately 
following the final neuroscore, animals were anesthetized with sevoflurane and sacrificed by 
cervical dislocation. The brain was carefully removed, frozen on powdered dry ice, and stored 
at -80°C.  Frozen brains were embedded in Optimal Cutting Temperature mounting media (Cell 
Path Ltd, Newton, Powys, UK) and cut in the coronal plane with a cryostat tissue slicer (Leica 
CM3050, Leica Microsystems, Milton Keynes, UK). For each brain a total of 16 – 18 sections (10 
µm thickness) were collected on Superfrost
®
 Plus microscope slides (Thermo Fisher Scientific, 
Loughborough, UK) every 500 µm. For the quantification of contusion volume, slices were stained 
with cresyl violet (Thermo Fisher Scientific, Loughborough, UK). Slices were imaged with a digital 
camera (Scopetek DCM510, Scopetek Opto-Eletric Co., Hangzhou, China) attached to a 
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stereomicroscope (Wild model M8, Heerbrugg, Switzerland).  The contusion was evident from a 
clear difference in the intensity of the cresyl-staining.  The area of the contusion was measured 
using image-analysis software (Scopephoto 3.1, Scopetek Opto-Eletric Co., Hangzhou, China) by 
an investigator blinded to the experimental groups.  Contusion volume was calculated by 
multiplying contusion areas, A, by the distance between brain sections, d, (500 µm), according to 
the following formula: 
𝑑
2
∗ (𝐴1 + 𝐴𝑛) + 𝑑 ∗ (𝐴2 + 𝐴3 + ⋯ + 𝐴𝑛−1) 
 Quantification of functional outcome. (i) Neuroscore. Functional outcome before and after 
CCI injury was determined using a 15-point neurological outcome score [41, 42]. The neuroscore 
consists of tasks evaluating locomotor ability, vestibulomotor function and general behaviour 
(Table 1). The neuroscore was performed in real time, before surgery and repeated at 24-hour 
intervals following CCI-injury, with the final test applied immediately before the animals were 
sacrificed (either 24 hours or 5 days after injury). Long term outcomes after 1 month were assessed 
using RotaRod and CatWalk-XT tests. (ii) RotaRod. Mice were placed on the RotaRod (Ugo Basile, 
Comerio, Italy). The RotaRod was accelerated linearly from 4 to 40 rev/minute over 5 minutes and 
the time the mouse remained on the drum recorded.  Three trials were performed with the longest 
time on the drum used. (iii) CatWalk-XT is an automated gait analysis system (Noldus Information 
Technology, Wageningen, The Netherlands), consisting of a glass plate with dim light illuminating 
the glass from the side. In a darkened environment (< 1 lux of illumination), light is reflected 
downward when the animal’s paws contact the glass surface. Images of the footprints are recorded 
by a video camera under the walkway. The images from each trial are processed and analysed on a 
PC by CatWalk-XT software. Three consecutive runs were performed and the mean values for the 
gait parameters for each animal were obtained. 
 Statistics. We assessed significance using either a Student’s t-test or one-way ANOVA, with 
Bonferroni's post-hoc test.  In the 5-day survival experiments we used two-way ANOVA with 
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repeated measures with Bonferroni's post-hoc test. Factor 1 was treatment (Xe, or control) and 
factor 2 was the time after injury (e.g. 1 day, 2 days, 3 days 4 days or 5 days).  We therefore used 
repeated measures ANOVA with factor 1 as the repeated factor. We used two-tailed hypothesis 
testing with p-values of less than 0.05 taken to indicate a significant difference between groups. The 
sample sizes (n) are indicated in the figure legends. From preliminary experiments with short-term 
outcomes (24 hour) we estimated that a sample size of ~10 animals in each treatment group would 
give a statistical power of ~0.80 (0.05A post-hoc power analysis of the results indicate that at 
a level of 0.05, the power of the experiments is on average 0.83 (range 0.55 to 0.98). Sample sizes 
for long-term behavioral experiments were estimated from previous experience with these tests. 
Where error bars are shown these are the standard error of the mean.  Statistical tests were 
implemented using SigmaPlot software (Systat Inc., Point Richmond, CA).  
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RESULTS (1109 words) 
Xenon pre-treatment and post-treatment is neuroprotective. We investigated the effect of 
xenon administration on neurological outcome and contusion volume when xenon was given both 
before & after, but not during, brain trauma (Figure 1). Treatment with 75% xenon:25% oxygen for 
2 hours immediately before the trauma and then for another 2 hours after the trauma resulted in a 
significant improvement (40 ± 11%, p<0.05) in functional neurological outcome 24 hours after 
trauma (Figure 1A). Contusion volume was reduced by 43 ± 7% (p<0.01) following xenon 
treatment (Figure 1B).  
Xenon post-treatment is neuroprotective.  We next determined whether xenon was effective 
when given only after traumatic brain injury.  We found that 75% xenon:25% oxygen administered 
15 minutes after injury for a period of 3 hours duration resulted in a 36 ± 6%  (p<0.05) 
improvement in neurological outcome score 24 hours after injury (Figure 2A).  We found that 
xenon treatment after injury significantly reduced contusion volume, by 19 ± 7% (p<0.05), 
compared to untreated controls (Figure 2B).   
Delayed xenon treatment is neuroprotective.  Having shown that xenon was effective when 
given immediately after injury, we determined the therapeutic time window in which xenon 
remained effective. We investigated the effect of delaying the start of the xenon treatment until 1 
hour, 3 hours or 6 hours after injury.  We found xenon-treatment begun 15 minutes, or 1 hour after 
injury significantly (p<0.05) improved the neurological outcome score 24 hours after injury by 33% 
and 46% respectively (Figure 3).  In the groups where xenon-treatment was delayed for 3 hours or 6 
hours there was a trend to improved neuroscore (27% and 26% respectively), but this did not reach 
statistical significance. We investigated the effect of delayed xenon treatment on contusion volume.  
We found xenon treatment starting 15 minutes, 1 hour or 3 hours after injury significantly (p<0.05) 
reduced total injury by ~20% (Figure 4), but delaying treatment until 6 hours after injury made the 
xenon-treatment ineffective (5.0 ± 0.2% reduction).     
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Concentration dependence of xenon's neuroprotective effect. We performed a series of 
experiments where animals were treated with 30% xenon:25% oxygen (balance nitrogen), 50% 
xenon:25% oxygen (balance nitrogen), 75% xenon:25% oxygen, or 75% nitrogen:25% oxygen, for 
3 hours, starting 15 minutes after injury.  Xenon reduced injury significantly (p<0.05) at all 
concentrations tested (Figure 5), by 19 ± 1%, at a concentration of 30%, by 17 ± 1% at a 
concentration of 50% and by 19 ± 2% at a concentration of 75% xenon.  Neurological outcome 
(data not shown) was significantly improved by treatment with 30% xenon or 75% xenon, by 45 ± 
10 % (p<0.05) and 67 ± 15 % (p<0.001) respectively. Treatment with 50% xenon resulted in a trend 
to reduction in neuroscore (24 ± 5 %) but this did not reach significance.   
Effect of xenon treatment on physiological parameters. In order to determine whether xenon 
treatment affected the physiology of the animals we measured blood pressure, heart rate and 
temperature in a cohort of animals that received CCI injury followed by 3 hours of treatment with 
either 75% xenon:25% oxygen or control gas, 75% nitrogen:25% oxygen, starting 15 minutes after 
injury.  There was no significant difference in physiological parameters between the xenon-treated 
or control-gas treated animals (Table 2).  
Effect of xenon up to 5 days post-injury. Neurological function was measured at 1 day, 2 
days, 3 days, 4 days and 5 days after injury (Figure 6).  Neurological outcome in the xenon-treated 
groups improved significantly (p<0.05) compared to the control group, up to 4 days after injury. On 
day 5, there was a trend for improvement in neurological outcome score in the xenon-treated group 
compared to the control group but this difference was not significant (p=0.06). 
Effect of xenon 1 month after injury. In order to establish whether xenon's protective effect 
persisted, a cohort of animals (N=50) were allowed to survive 1 month after traumatic injury.  Two 
groups underwent CCI surgery followed by treatment with either 75% xenon:25 % oxygen or 75% 
nitrogen:25 % oxygen, starting 15 minutes after injury, for 3 hours duration, a third group 
underwent sham-surgery including anesthesia, skin-incision with exposure of skull, but no 
12 
 
craniotomy or TBI impact. The duration of anaesthesia and time between skin incision and suturing 
was identical to the CCI-surgery group. The sham group received treatment with 75% nitrogen:25 
% oxygen for 3 hours.  One month after injury we examined performance on the RotaRod to 
determine whether this revealed a locomotor deficit (Figure 7). There was no difference in Rota-
Rod performance between the control-gas treated TBI group or the sham-surgery group or the 
xenon-treated TBI group, indicating that the RotaRod is not a suitable outcome at this timepoint.  
We tested the animals using the CatWalk-XT gait-analysis system in order to determine whether 
more subtle measures of locomotor function would reveal a deficit. There was a significant 
(p<0.05) deficit in locomotor running-speed in the control TBI-group (43 ± 3 cm/sec) compared to 
the sham-surgery group (53 ± 3 cm/sec).  Xenon-treatment improved the deficit in running speed 
(50 ± 2 cm/sec); there was no significant difference (p=0.65) between the xenon-treated TBI group 
and the sham-surgery group (see Figure 8A).  We next examined the base-of-support for front and 
hind paws (Figure 8B). The base-of-support (BOS) measures distance between mid-points of the 
front paws or rear paws during locomotion. There was no change in the BOS of the front paws. 
However, there was a trend to increase in the BOS of the rear paws in control-TBI group (33 ± 4 
mm) compared to sham-operated animals (24 ± 4 mm), but this was not significant.  Xenon-
treatment prevented the increase in BOS; there was no significant difference between the xenon-
treated TBI group (25 ± 4 mm) and the sham-surgery group.  The increase in BOS observed in the 
rear paws is consistent with the observation in the short-term neuroscore results that faults in rear-
paw placement occur. We observed a trend towards a reduction in cadence (Figure 8C) in the TBI-
control group compared to sham-surgery group (p=0.06). This trend was absent in the xenon-treated 
TBI group. To determine whether there were specific locomotor deficits in particular limbs we 
examined the swing speed for each limb (Figure 8D). Swing speed is calculated from stride-length 
and time between paw placements for each limb. We found there was a locomotor deficit for each 
paw in the TBI-control group compared to sham-surgery group. This was significant (p<0.05) for 
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all paws except the hind left which showed a trend (p=0.06). Interestingly, the deficit in the right 
hind paw was the largest (22 ± 2% reduction) and this was highly significant (p<0.01). Xenon-
treatment prevented the locomotor deficit; in all cases the xenon-treated TBI group was not 
significantly different to the sham-surgery group.  
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DISCUSSION (1173 words)   
The findings presented here are the first to show that xenon is neuroprotective in an animal model 
of traumatic brain injury. We show that xenon treatment improves functional neurological outcome 
and reduces secondary injury development, even when commencement of the xenon treatment is 
delayed 1-3 hours following trauma.  Our findings are consistent with previous in vitro studies 
showing xenon is neuroprotective in an in vitro model of traumatic brain injury [43, 44], using 
mouse organotypic hippocampal slice cultures subjected to focal mechanical injury and with cell-
injury quantified by propidium-iodide fluorescence.  Such in vitro models are useful in screening 
putative neuroprotectants and understanding their mechanism of action [44], but cannot model 
behavioral neurological outcome. Hence, it is important to test putative neuroprotectants such as 
xenon in pre-clinical models that allow assessment of improvements in functional neurological 
outcome at clinically relevant timepoints. 
 Experimental model.  We investigated the neuroprotective efficacy of the noble gas xenon in 
an in vivo mouse model of traumatic brain injury. We used male animals to exclude effects of the 
estrous cycle and any potential confounding neuroprotective effects of female sex hormones. The 
rodent CCI model we used has been widely used in pre-clinical TBI studies [45-52] and is highly 
reproducible.  In our experiments with xenon we chose to investigate the effects of xenon on both 
acute outcome 1-5 days after injury and long term outcome 1 month after injury.  
 Xenon pre-treatment and post-treatment.  In both in vitro and in vivo models of ischemic 
injury there is evidence that xenon treatment before injury protects neuronal and cardiac tissue [53-
61].  We reasoned that giving xenon both before and after traumatic injury would be protective.  
Our results show that 75% xenon:25% oxygen given for 2 hours immediately before injury and then 
for a further 2 hours after trauma significantly improves neurological outcome (p<0.05) and reduces 
contusion volume (p<0.01) 24 hours after injury. It is possible that xenon could be used before 
traumatic injury, e.g. in neurosurgical procedures, to minimize damage to neighboring healthy 
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tissue. Nevertheless, in an accidental TBI, such as a motor-vehicle crash, xenon pre-treatment 
would obviously not be possible. 
 Xenon post-treatment. The main objective of our study was to evaluate xenon’s potential as 
a treatment for TBI in clinically relevant settings. We therefore determined the effect of xenon 
treatment, when xenon was given only after the trauma.  We chose a xenon treatment time of 3 
hours based on previous studies with xenon in in vivo ischemic injury models [30, 62].  We chose 
15 minutes post-injury as the earliest start time for xenon treatment, based on a scenario that a TBI 
patient could receive medical attention at the scene of injury within 15-20 minutes.  Our results 
show that giving xenon for 3 hours after injury results in a significant (p<0.05) reduction in 
contusion volume when xenon was given at concentrations of 30%, 50% or 75%.  
 Therapeutic time-window for xenon treatment. One of the most important considerations for 
a potential treatment for TBI is whether there is a clinically relevant time-window within which 
treatment is effective. We investigated the effect of delaying xenon treatment until 1 hour, 3 hours 
or 6 hours after injury.  When xenon treatment was delayed up to 3 hours after injury, there was a 
significant (p<0.05) reduction in contusion volume, but delaying treatment for 6 hours did not result 
in reduction of contusion.  Our findings also show a significant (p<0.05) improvement in 
neurological outcome when treatment is delayed up to at least 1 hour after injury.  
 Effect of xenon up to 5 days after trauma. The untreated-TBI animals showed an 
improvement in neurological outcome over the course of 5 days. This underlying improvement in 
control neuroscore may reflect both an recovery in locomotor function and a component of learning 
on successive test days.  Nevertheless, on each measurement day, the xenon-treated group had an 
better neurological score, by 42% on average, compared to the un-treated group. The improvement 
with xenon-treatment was significant (p<0.05) up to day 4 after injury. The neurological severity 
score measurement we used has been shown to be a good predictor of long-term outcome and to 
correlate with injury severity assessed by MRI [42].   
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Locomotor outcomes 1 month after injury.  In human TBI patients long-term impairments 
have the greatest financial and social cost.  In order that our results have clinical relevance we 
examined the effect of xenon-treatment on behavioral outcomes 1 month after traumatic injury.  
TBI patients frequently report postural instability that persists years after the trauma [63, 64]. 
Studies using analysis of gait in TBI patients have revealed deficits compared to healthy controls.  
The CatWalk-XT gait-analysis system has been used to measure deficits in a variety of rodent 
brain-injury models [65-68]. Gait analysis one month after injury revealed significant (p<0.05) 
deficits in the TBI group, in locomotor speed and in the swing speed of all four limbs.  Remarkably, 
none of these deficits were present in the xenon-treated TBI group. We also observed a trend to 
increase in base of support of hind limbs in the TBI group that was absent in the xenon treated 
group. These findings are of particular clinical relevance because deficits in walking speed and base 
of support are observed in TBI patients [69-71]. A recent systematic review of studies in TBI 
patients found that in all studies that reported speed, TBI patients walked more slowly than healthy 
controls [72]. Our results indicate that xenon-treatment may prevent these persistent locomotor 
deficits in TBI patients.  
Clinical relevance of these findings.  Xenon has many properties of an ideal general 
anesthetic [20], but its widespread use has been limited, in part due to its cost.  Since the discovery 
that xenon was an NMDA receptor antagonist [24] and the subsequent demonstration that xenon has 
neuroprotective properties in models of ischemic injury [25-34] there has been a resurgence of 
interest in the use of xenon as a neuroprotectant. Clinical trials are currently evaluating xenon in 
different types of ischemic injury (e.g. neonatal asphyxia, brain damage after cardiac arrest [35, 
36]).  In this study we have shown for the first time that xenon is protective against blunt-traumatic 
brain injury, in the controlled cortical impact rodent model. Our results show that xenon treatment 
reduces secondary injury, improves neurological outcome both acutely and 1 month after injury, 
and that xenon has a clinically relevant therapeutic time-window of up to 3 hours.  The fact that 
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xenon is effective at a concentration of 30% is particularly relevant to the treatment of patients with 
severe TBI where it may be necessary to give increased concentrations of oxygen.  The duration of 
xenon treatment we used is relatively short (3 hours) and it is possible, indeed likely, that extending 
this treatment time would result in a greater degree of neuroprotection and/or a longer therapeutic 
time window. A recent clinical study in cardiac-arrest patients has shown that it is practical to give 
xenon to patients in the ITU for up to 24 hours [36].  Our findings support the idea that xenon could 
provide a realistic first-line treatment for brain-trauma patients and further research in this area is 
warranted. 
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Table 1: Criteria for the neurological outcome score. Points are scored for the failure to 
successfully perform a task, up to a maximum of 15 points for severe impairment. Healthy animals 
scored 0 points.  Modified from Tsenter et al [42]  * no response to handclap # does not explore 
environment  
 
Task Points 
Failure to exit a 25 cm diameter circle in 30 sec 
Failure to exit a 25 cm diameter circle in 60 sec 
Failure to exit a 25 cm diameter circle in 120 sec 
1 
1 
1 
Inability/impaired ability to traverse a 3 cm wide beam 2/1 
Inability/impaired ability to traverse a 2 cm wide beam 2/1 
Inability/impaired ability  to traverse a 1 cm wide beam 2/1 
Inability to balance on a 0.5 cm diameter round stick  1 
Inability to balance on a 0.5 cm square stick 1 
Presence of hemiparesis 1 
Inability to walk in a straight line 1 
Loss of startle reflex * 1 
Lack of exploratory behaviour # 1 
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Table 2.  Physiological measurements. Treatment with 75% xenon:25% oxygen for 3 hours, 
starting 15 minutes after trauma had no effect on blood pressure, heart rate or temperature compared 
to 75% nitrogen:25% oxygen control.  Data shown below are individual values for each animal 
(n=16) together with mean and SEM for each group.  There were no significant differences between 
control or xenon treatment groups for systolic or diastolic blood pressure (p=0.49, p=0.43), heart 
rate (p=0.36) or temperature (p=0.53).  
 
 
 
  
treatment Systolic BP 
(mm Hg) 
Diastolic BP 
(mm Hg) 
Heart Rate 
min-1 
Temperature 
°C 
     
control 179 150 493 36.7 
control 162 129 487 n.d. 
control 165 135 482 n.d. 
control 157 124 540 36.6 
control 146 114 462 35.9 
control 132 106 344 37.3 
control 171 149 452 37.7 
control 170 130 400 37.1 
     
mean ± SEM 160 ± 5 
 
130 ± 5 458 ± 21 36.9 ± 0.2 
75% xenon  171 133 424 37.4 
75% xenon 143 101 431 36.5 
75% xenon 166 140 389 36.8 
75% xenon 143 120 552 36.7 
75% xenon 162 137 484 37.4 
75% xenon 145 112 425 36.8 
75% xenon 164 136 401 37.3 
75% xenon 150 109 310 37.6 
     
mean ± SEM 156  ± 4 
 
124 ± 5 427 ± 25 37.0 ± 0.1 
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Figure 1.  Treatment with xenon before and after injury (A) improves neurological outcome and 
(B) reduces contusion volume following trauma.  Xenon-treated animals (grey bars) received 75% 
xenon : 25% oxygen for 2 hours before injury and for 2 hours after injury. Control animals (white 
bars) received 75% nitrogen : 25% oxygen. Neurological outcome and contusion volume were 
measured 24 hours after trauma. Bars represent mean values and error bars are standard errors 
(control n=6, xenon n=6). * = p<0.05; ** = p<0.01, compared to control. 
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Figure 2.  Treatment with xenon after injury (A) improves neurological outcome and (B) reduces 
contusion volume following trauma.  Xenon-treated animals (grey bars) received 75% xenon : 25% 
oxygen for 3 hours duration, 15 minutes after trauma. Control animals (white bars) received 75% 
nitrogen : 25% oxygen. Neurological outcome and contusion volume were measured 24 hours after 
trauma. Bars represent mean values and error bars are standard errors (Neurological outcome: n=22, 
control; n=21, xenon; Contusion volume: n=22, control; n=9 xenon) * = p<0.05 compared to 
control.  
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Figure 3.  Delayed xenon treatment following trauma improves neurological outcome 24 hours 
after trauma. Xenon-treated animals (grey bars) received 75% xenon : 25% oxygen for 3 hours 
duration, starting at 15 minutes, 1 hour, 3 hours or 6 hours after trauma. Control animals (white bar) 
received 75% nitrogen : 25% oxygen. Neurological outcome was measured 24 hours after trauma. 
Bars represent mean values and error bars are standard errors (n=34, control; n=21, xenon 15 min; 
n=8, xenon 1 hr; n=9, xenon 3 hr; n=9, xenon 6 hr) * = p<0.05 compared to control. 
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Figure 4.  Delayed xenon treatment following trauma reduces injury 24 hours after trauma. (A) 
Typical cresyl-violet stained slices, 2.2 mm posterior to Bregma, showing primary injury 15 min 
after trauma, control injury and xenon-treated injury at 24 hours after trauma. In example shown 
xenon treatment was delayed until 1 hour after trauma. (B) Xenon-treated animals (grey bars) 
received 75% xenon : 25% oxygen for 3 hours duration starting at 15 minutes, 1 hour, 3 hours or 6 
hours after trauma. Control animals (white bar) received 75% nitrogen:25% oxygen. Contusion 
volume was measured 24 hours after trauma. Bars represent mean values and error bars are standard 
errors (n=22, control; n=9, xenon 15 min; n=8, xenon 1 hr; n=9, xenon 3 hr; n=9, xenon 6 hr) 
* = p<0.05; ** = p<0.01 compared to control. 
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Figure 5.  Xenon is neuroprotective at concentrations of 30%, 50% and 75%. Xenon-treated 
animals (grey bars) received 75% xenon : 25% oxygen, 50% xenon, 25% oxygen, 25% nitrogen or 
30% xenon, 25% oxygen, 45% nitrogen for 3 hours duration starting at 15 minutes after trauma. 
Control animals (white bar) received 75% nitrogen : 25% oxygen. Contusion volume was measured 
24 hours after trauma. Bars represent mean values and error bars are standard errors (n=9, control; 
n=9, xenon 75%  ; n=7, xenon 50% ; n=9, xenon 30%;) * = p<0.05, ** = p<0.01 compared to 
control. 
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Figure 6.  Xenon treatment improves neurological outcome up to 4 days after trauma. Xenon-
treated animals (grey bars) received 75% xenon:25% oxygen, for 3 hours duration, starting 15 
minutes after trauma. Control animals (white bars) received 75% nitrogen:25% oxygen. 
Neurological outcome was measured at 1 day intervals for 5 days after trauma. Bars represent mean 
values and error bars are standard errors (day 1: n=22, control; n=21, xenon;  day 2-3: n=12, 
control; n=12, xenon; day 4-5: n=11, control; n=12, xenon) * = p<0.05; ** = p<0.01; *** = p<0.001 
compared to control. 
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Figure 7. Performance on RotaRod does not reveal motor deficit.  There was no difference in 
Rotarod performance between sham-operated animals, CCI injury or CCI injury with 75% xenon 
treatment for 3 hours duration, starting at 15 minutes after trauma.  The test was performed 1 month 
after injury or sham-surgery. Bars represent mean values and error bars are standard errors (n=10, 
sham; n=20, TBI; n=20, TBI + xenon). 
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Figure 8 Xenon improves locomotor deficits 1 month after injury.  CatWalk-XT gait-analysis tests 
reveals deficits in locomotor speed, base of support and swing speed that are prevented by  
treatment with 75% xenon for 3 hours duration, starting at 15 minutes after trauma. A) There is a 
significant reduction in locomotor speed in TBI-injured animals compared to sham-operated 
controls.  Xenon-treated TBI-injured animals are not significantly different to sham-operated 
controls. B) Base of support (average separation) of the hind paws was increased in the TBI group 
compared to sham-operated controls or xenon-treated TBI group, but this did not reach significance. 
C) Cadence was reduced in the TBI group compared to sham-surgery group, but this did not reach 
significance (p=0.06). D) Analysis of individual limb speed shows a significant reduction in TBI-
injured animals in front left, front right and right hind limb speed compared to sham-operated 
animals. Xenon-treated TBI-injured animals are not significantly different to sham-operated 
controls. Bars represent mean values of sham (white), TBI-injury (black) and xenon-treated TBI 
injury groups (grey). The error bars are standard errors (n=9 sham, n=19, TBI, n=19 TBI + xenon). 
* = p<0.05, ** = p<0.01 compared to sham-operated control. 
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